Results 91 to 100 of about 2,976 (190)

HER-2/neu overexpression in breast cancer

مجلة كلية الطب, 2010
Background: In breast carcinoma, amplification &/or over-expression of HER-2/neu has been associated with a group of unfavorable prognostic factors. The Food & Drug Administration Agency approved Trastuzumab (Herceptin) for the therapy of metastatic ...
Rana S. Aziz, Nabeel W. Rasheed
doaj   +1 more source

Single-day HER2neu amplification assessment using chip-based digital PCR in formalin-fixed paraffin-embedded breast carcinoma tissue

Breast Cancer: Targets and Therapy, 2018
Human epidermal growth factor receptor 2 (HER2) amplification is present in almost 15%-20% of breast cancer tumors, making it an important parameter for testing. The present study was designed to evaluate a chip-based digital PCR (dPCR) system for assessing HER2 amplification from formalin-fixed paraffin-embedded breast carcinoma tissue and to compare ...
Parth Shah, Shiva Murarka, Anupam Joshi, Bhavana Mehta, Vipal Parmar, Nidhi Shah, Khushbu Patel, Jacob Sands   +7 more
openaire   +5 more sources

The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population [PDF]

, 2013
Background: Breast cancer in the elderly is associated with high recurrence and death rates, due mostly to undertreatment. Human epidermal growth factor receptor type 2 (HER2) overexpression is infrequent in older patients.
Adamo, B., Adamo, V., Caristi, N., Cicero, G., Ferraro, G., Franchina, T., Ricciardi, G., Rizzo, S., Rossello, R., Russo, A., Zanghi, M.   +10 more
core   +1 more source

Correlation between grade of the tumour and HER2NEU status in breast cancer.

The Professional Medical Journal
Objective: To evaluate the distribution of histological grades of breast cancer and its association with HER2/neu expression. Study Design: Cross-sectional study. Period: March 2024 to August 2024. Setting: Oncology, Jinnah Postgraduate Medical Center, Karachi, Pakistan.
null Faiza Mahar, null Ghulam Haider, null Priyanka, null Saima Zahoor   +3 more
openaire   +1 more source

High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. [PDF]

, 2016
Automated methods are needed to facilitate high-throughput and reproducible scoring of Ki67 and other markers in breast cancer tissue microarrays (TMAs) in large-scale studies. To address this need, we developed an automated protocol for Ki67 scoring and
Abubakar, Mustapha, Benitez, Javier, Blows, Fiona, Bolla, Manjeet K, Brenner, Herman, Broeks, Annegien, Chang-Claude, Jenny, Couch, Fergus J, Coulson, Penny, Daley, Frances, Devilee, Peter, Dowsett, Mitch, Easton, Douglas, Eccles, Diana, Figueroa, Jonine, Garcia-Closas, Montserrat, Hewitt, Stephen, Hm van Deurzen, Carolien, Hollestelle, Antoinette, Hooning, Maartje J, Howat, William J, Jones, Michael, kConFab Investigators, Lissowska, Jolanta, Mannermaa, Arto, McDuffus, Leigh-Anne, Milne, Roger, Orr, Nick, Pharoah, Paul D, Raza Ali, H, Rudolph, Anja, Schmidt, Marjanka K, Schoemaker, Minouk, Sherman, Mark E, Sinn, Peter, Stegmaier, Christa, Swerdlow, Anthony J, Tollenaar, Rob AEM, van Leeuwen, Flora E, Van't Veer, Laura, Wang, Qin, Wm Martens, John, Zabaglo, Lila   +42 more
core   +2 more sources

Breast Cancer Patients with Her2neu Overexpression: Relationship among Clinicopathological Characteristics and Local/Distant Recurrences and Survival

Annals of Oncology, 2012
ABSTRACT Objectives The aim of this study was to correlate the overexpression of HER2 with clinical pathologic characteristics and its influence on local/distant recurrence and survival. Methods From 1998 to 2010, prospective data of 146 patients with invasive breast cancer with HER-2 overexpression was studied. The sample was divided into three
C. Bellido-Ribes, S. Gonzalez, A. Garcia, V. Obadia, R. Bastus, J. Fernández, A. Aguilar, L. Cirera   +7 more
openaire   +1 more source

Monitoring Therapy by Serum HER-2/Neu

The International Journal of Biological Markers, 2000
We have evaluated the performance of the Bayer Immuno 1™ serum HER-2/neu assay. The precision is excellent and varied between 1.7% and 2.1% at values of HER-2/neu ranging from 16.8 ng/mL to 108.6 ng/mL.
M.K. Schwartz MD, C. Smith, D.C. Schwartz, A. Dnistrian, I. Neiman   +4 more
doaj   +1 more source

Оценка патоморфоза после неоадъювантной терапии рака молочной железы [PDF]

, 2019
МОЛОЧНОЙ ЖЕЛЕЗЫ НОВООБРАЗОВАНИЯРАК МОЛОЧНОЙ ЖЕЛЕЗЫНЕОАДЪЮВАНТНАЯ ТЕРАПИЯЛЕЧЕБНЫЙ ПАТОМОРФОЗЦель – систематизировать имеющиеся данные о лечебном патоморфозе опухоли молочной железы после неоадьювантной системной терапии (НАТ).
Ачинович, С. Л., Ганусевич, О. Н., Нестерович, Т. Н., Федоркевич, И. В.   +3 more
core  

The Clinical Significance of Unknown Sequence Variants in BRCA Genes [PDF]

, 2010
: Germline mutations in BRCA1/2 genes are responsible for a large proportion of hereditary breast and/or ovarian cancers. Many highly penetrant predisposition alleles have been identified and include frameshift or nonsense mutations that lead to the ...
BRUNO, Loredana, Calò, V, DI GAUDIO, Francesca, LA PAGLIA, Laura, MARGARESE, Naomi, PEREZ, Marco, RUSSO, Antonio   +6 more
core   +3 more sources

Management of Diffuse Carcinomatosis of the Bone Marrow from Occult Breast Cancer with Abemaciclib and Letrozole: Case Report and Literature Review

Indian Journal of Medical and Paediatric Oncology
Occult breast cancer (OBC) signifies a rare subset of breast cancers, accounting for only 0.3 to 1% of all breast cancers. Diagnosing cancer of unknown primary requires a comprehensive approach, including histological examination, immunohistochemistry ...
Ketan Makwana, Shaunak Valame
doaj   +1 more source